Economic modelling
An economic model has to survive review by people looking for its weak points. We build models that are transparent in structure, clear about their assumptions and simple to adapt from one market to the next.
We develop early models that guide development and pricing decisions, and submission-ready models for HTA. Analyses include cost-effectiveness (CEA), cost-utility (CUA), cost-minimisation (CMA) and budget impact (BIM).
The structure follows the disease and the decision: decision trees, Markov models and partitioned survival models (PSM). We build de novo models and adapt existing global models to country requirements.
What we deliver
- Cost-effectiveness and cost-utility analyses (CEA, CUA)
- Cost-minimisation analyses (CMA)
- Budget impact models (BIM)
- Decision tree, Markov and partitioned survival models
- De novo model development
- Country-specific model adaptation
Related publications from our team
Common questions
What is the difference between a cost-effectiveness model and a budget impact model?
A cost-effectiveness model estimates the extra cost per unit of health gained, usually per quality-adjusted life year, compared with existing care. A budget impact model estimates what adopting the treatment will cost a specific payer over the next few years.
What is an early economic model?
An early model is built before pivotal data are available. It tests which assumptions drive value, which evidence gaps matter most, and what price the product could support, so development and evidence plans can respond.
Patients should not be left waiting for treatments that can change their lives.
We are committed to a healthcare system where value is measured fairly and decisions are guided by sound evidence. Tell us what you are working on and we will show you how we would approach it.
